Thromboprophylaxis in pregnancy

Article

Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is one of the most common, serious complications associated with pregnancy.

Key Points

Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is one of the most common, serious complications associated with pregnancy, and now ranks as a leading cause of maternal morbidity and mortality in developed countries.1 Information regarding the association of VTE with acquired and heritable thrombophilias and other high-risk conditions has greatly expanded during the last 2 decades, adding a new layer of complexity to decisions about thromboprophylaxis. In addition, updated guidelines regarding VTE and pregnancy have been published recently by the Royal College of Obstetricians and Gynaecologists (RCOG), the American College of Obstetricians and Gynecologists (ACOG), and the American College of Chest Physicians (ACCP).2-4 The objective of this review is to discuss which patients have a clinically important increased risk of VTE; of them, who needs thromboprophylaxis; and which management regimens to use in specific patient subgroups.

Mechanism of increased VTE risk in pregnancy

Pregnancy and the postpartum period carry an increased likelihood of VTE, with the frequency cited as 0.61 to 1.72 per 1,000 deliveries.5,6 Pregnant and postpartum women are thus approximately 4 to 5 times more likely to develop VTE than age-matched nonpregnant women.7 Although findings vary somewhat from study to study, roughly equal proportions of clinically apparent, pregnancy-related VTE events are diagnosed in the antepartum and postpartum periods.6 However, the frequency of VTE per unit of time (such as per week postpartum) is as much as 5 times greater postpartum than for the antepartum period.7

Recent Videos
March of Dimes 2024 Report highlights preterm birth crisis | Image Credit: marchofdimes.org
Understanding and managing postpartum hemorrhage: Insights from Kameelah Phillips, MD | Image Credit: callawomenshealth.com
Rossella Nappi, MD, discusses benefits of fezolinetant against vasomotor symptoms | Image Credit: imsociety.org
How AI is revolutionizing breast cancer detection | Image Credit: simonmed.com
Understanding cardiovascular risk factors in women | Image Credit: cedars-sinai.org.
Christie Hilton, DO, discusses breast cancer management | Image Credit: findcare.ahn.org
Updated FLUBLOK label expands influenza vaccine options for pregnant women | Image Credit: mass-vaccination-resources.org
Sheryl Kingsberg, PhD: Psychedelic RE104 for postpartum depression
Mammograms may reveal hidden cardiovascular risks, study finds | Image Credit: providers.ucsd.edu
Related Content
© 2024 MJH Life Sciences

All rights reserved.